Literature DB >> 22969930

microRNA-192, -194 and -215 are frequently downregulated in colorectal cancer.

Yeunpo Chiang1, Yongxi Song, Zhenning Wang, Zhuangkai Liu, Peng Gao, Jiwang Liang, Jinliang Zhu, Chengzhong Xing, Huimian Xu.   

Abstract

microRNAs (miRNAs) are small, non-coding RNAs of endogenous origin. They have been increasingly shown to have aberrant expression in a number of tumor types. miR-192, -194 and -215 have not been comprehensively investigated using a large number of cases in colorectal cancer (CRC). We extracted total RNA from 107 CRC tissues and three CRC cell lines. Following polyadenylation and reverse transcription, the expression levels of miR-192, -194 and -215 were determined for evaluation of the association between expression levels and clinicopathological characteristics by a quantitative real-time polymerase chain reaction (real-time PCR) method. Finally, we studied the impact of miR-194 on cell proliferation in HCT-116 cells by MTT assay. miR-192, -194 and -215 were significantly downregulated in CRC tissues (all p<0.001, paired t-test) and cancer cell lines (all p<0.05) compared to non-tumor counterparts. Moreover, the expression levels of miR-192, -194 and -215 were demonstrated to be associated with increased tumor sizes (p=0.027, p=0.018, and p=0.027, respectively; Mann-Whitney U test). Also, there were marked correlations among these miRNAs in CRC tissues (all p<0.001, Pearson's regression analysis). Furthermore, we found that the overexpression of miR-194 could significantly inhibit cell proliferation in HTC-116 cells. miR-192, -194 and -215 may be important biological markers as tumor suppressors in the carcinogenesis of CRC.

Entities:  

Year:  2011        PMID: 22969930      PMCID: PMC3438543          DOI: 10.3892/etm.2011.436

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  32 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  The colorectal microRNAome.

Authors:  Jordan M Cummins; Yiping He; Rebecca J Leary; Ray Pagliarini; Luis A Diaz; Tobias Sjoblom; Omer Barad; Zvi Bentwich; Anna E Szafranska; Emmanuel Labourier; Christopher K Raymond; Brian S Roberts; Hartmut Juhl; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

Review 3.  microRNA and cancer.

Authors:  Mengfeng Li; Jun Li; Xiaofan Ding; Mian He; Shi-Yuan Cheng
Journal:  AAPS J       Date:  2010-04-28       Impact factor: 4.009

4.  Altered expression of MiR-148a and MiR-152 in gastrointestinal cancers and its clinical significance.

Authors:  Yue Chen; Yongxi Song; Zhenning Wang; Zhenyu Yue; Huimian Xu; Chengzhong Xing; Zhuangkai Liu
Journal:  J Gastrointest Surg       Date:  2010-04-27       Impact factor: 3.452

5.  Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs.

Authors:  Lee P Lim; Nelson C Lau; Philip Garrett-Engele; Andrew Grimson; Janell M Schelter; John Castle; David P Bartel; Peter S Linsley; Jason M Johnson
Journal:  Nature       Date:  2005-01-30       Impact factor: 49.962

6.  Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215.

Authors:  Sara A Georges; Matthew C Biery; Soo-Yeon Kim; Janell M Schelter; Jane Guo; Aaron N Chang; Aimee L Jackson; Michael O Carleton; Peter S Linsley; Michele A Cleary; B Nelson Chau
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

7.  Unique microRNA molecular profiles in lung cancer diagnosis and prognosis.

Authors:  Nozomu Yanaihara; Natasha Caplen; Elise Bowman; Masahiro Seike; Kensuke Kumamoto; Ming Yi; Robert M Stephens; Aikou Okamoto; Jun Yokota; Tadao Tanaka; George Adrian Calin; Chang-Gong Liu; Carlo M Croce; Curtis C Harris
Journal:  Cancer Cell       Date:  2006-03       Impact factor: 31.743

8.  Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells.

Authors:  Bo Song; Yuan Wang; Matthew A Titmus; Galina Botchkina; Andrea Formentini; Marko Kornmann; Jingfang Ju
Journal:  Mol Cancer       Date:  2010-04-30       Impact factor: 27.401

9.  Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development.

Authors:  Flavia Pichiorri; Sung-Suk Suh; Alberto Rocci; Luciana De Luca; Cristian Taccioli; Ramasamy Santhanam; Wenchao Zhou; Don M Benson; Craig Hofmainster; Hansjuerg Alder; Michela Garofalo; Gianpiero Di Leva; Stefano Volinia; Huey-Jen Lin; Danilo Perrotti; Michael Kuehl; Rami I Aqeilan; Antonio Palumbo; Carlo M Croce
Journal:  Cancer Cell       Date:  2010-10-19       Impact factor: 31.743

10.  MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation.

Authors:  Yong-Xi Song; Zhen-Yu Yue; Zhen-Ning Wang; Ying-Ying Xu; Yang Luo; Hui-Mian Xu; Xue Zhang; Li Jiang; Cheng-Zhong Xing; Yong Zhang
Journal:  Mol Cancer       Date:  2011-01-04       Impact factor: 27.401

View more
  45 in total

1.  Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer.

Authors:  Gholam Basati; Amirnader Emami Razavi; Iraj Pakzad; Fardin Ali Malayeri
Journal:  Tumour Biol       Date:  2015-08-29

Review 2.  MicroRNAs in colorectal cancer as markers and targets: Recent advances.

Authors:  Jing-Jia Ye; Jiang Cao
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

3.  MicroRNA-215 inhibits relapse of colorectal cancer patients following radical surgery.

Authors:  Shan Li; Jing Gao; Jin Gu; Jiajia Yuan; Dong Hua; Lin Shen
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

4.  A Highly Predictive Model for Diagnosis of Colorectal Neoplasms Using Plasma MicroRNA: Improving Specificity and Sensitivity.

Authors:  Jane V Carter; Henry L Roberts; Jianmin Pan; Jonathan D Rice; James F Burton; Norman J Galbraith; Maurice R Eichenberger; Jeffery Jorden; Peter Deveaux; Russell Farmer; Anna Williford; Ziad Kanaan; Shesh N Rai; Susan Galandiuk
Journal:  Ann Surg       Date:  2016-10       Impact factor: 12.969

5.  Differential expression of microRNA-320a, -145, and -192 along the continuum of normal mucosa to high-grade dysplastic adenomas of the colorectum.

Authors:  Vassiliki L Tsikitis; Ian White; Motomi Mori; Amiee Potter; Achyut Bhattcharyya; Stanley R Hamilton; Julie Buckmeier; Peter Lance; Patricia Thompson
Journal:  Am J Surg       Date:  2014-03-12       Impact factor: 2.565

6.  MiR-215/192 participates in gastric cancer progression.

Authors:  Y J Xu; Y Fan
Journal:  Clin Transl Oncol       Date:  2014-07-01       Impact factor: 3.405

7.  Post-transcriptional regulation of cardiac sodium channel gene SCN5A expression and function by miR-192-5p.

Authors:  Yuanyuan Zhao; Yuan Huang; Weihua Li; Zhijie Wang; Shaopeng Zhan; Mengchen Zhou; Yufeng Yao; Zhipeng Zeng; Yuxi Hou; Qiuyun Chen; Xin Tu; Qing K Wang; Zhengrong Huang
Journal:  Biochim Biophys Acta       Date:  2015-07-21

8.  MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway.

Authors:  Bo Wang; Zhan-long Shen; Zhi-dong Gao; Gang Zhao; Chun-you Wang; Yang Yang; Ji-zhun Zhang; Yi-chao Yan; Chao Shen; Ke-wei Jiang; Ying-jiang Ye; Shan Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Mir-192 suppresses apoptosis and promotes proliferation in esophageal aquamous cell caicinoma by targeting Bim.

Authors:  Shujun Li; Feng Li; Ren Niu; Helin Zhang; Airong Cui; Wenting An; Xiaolu Wang
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 10.  MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.

Authors:  Verena Stiegelbauer; Samantha Perakis; Alexander Deutsch; Hui Ling; Armin Gerger; Martin Pichler
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.